Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 14/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5797203 | 0.88 | DRD2 (0.47) | F10CHEK1KDM4EALDH1A1HPGD | |
| SCHEMBL5917599 | 0.79 | CHEK1 (0.52) | CHEK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5795587 | 0.77 | F10 (0.55) | F10CHEK1KDM4EALDH1A1HPGD | |
| SCHEMBL5796117 | 0.74 | CHEK1 (0.58) | CHEK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5917615 | 0.72 | HRH3 (0.52) | CHEK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5917611 | 0.72 | CHEK1 (0.46) | CHEK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5795808 | 0.72 | CHEK1 (0.45) | CHEK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5809818 | 0.71 | KMT2A (0.42) | CHEK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5917635 | 0.71 | HRH4 (0.46) | CHEK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5793647 | 0.70 | HRH4 (0.47) | CHEK1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006035308-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-04-06 | — | — | WO | claimed |
| US-20060069087-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2006-03-30 | — | — | US | claimed |
| WO-2006035308-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069087-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069087-A1 | Histamine-3 receptor antagonists | HRH3, HRH4, HRH2 | F10 2932/4885CHEK1 2994/4885KDM4E 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.